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Disruption of Platelet-Derived Growth Factor–Dependent
Phosphatidylinositol 3-Kinase and Phospholipase C 1
Activity Abolishes Vascular Smooth Muscle Cell Proliferation
and Migration and Attenuates Neointima Formation In Vivo
Evren Caglayan, MD,*† Marius Vantler, PHD,*† Olli Leppänen, MD,‡ Felix Gerhardt, MD,*
Lenard Mustafov, MD,* Henrik ten Freyhaus, MD,* Kai Kappert, MD,§ Margarete Odenthal, MD,
Wolfram H. Zimmermann, MD,¶ Michelle D. Tallquist, PHD,# Stephan Rosenkranz, MD*†
Köln, Berlin, and Göttingen, Germany; Gävle, Sweden; and Dallas, Texas
Objectives We tested the hypothesis whether selective blunting of platelet-derived growth factor (PDGF)–dependent vascu-
lar smooth muscle cell (VSMC) proliferation and migration is sufficient to prevent neointima formation after vas-
cular injury.
Background To prevent neointima formation and stent thrombosis after coronary interventions, it is essential to inhibit VSMC
proliferation and migration without harming endothelial cell function. The role of PDGF—a potent mitogen and
chemoattractant for VSMC that does not affect endothelial cells—for neointima formation remains controversial.
Methods To decipher the signaling pathways that control PDGF beta receptor (PDGFR)–driven VSMC proliferation and
migration, we characterized 2 panels of chimeric CSF1R/PDGFR mutants in which the binding sites for
PDGFR-associated signaling molecules (Src, phosphatidylinositol 3-kinase [PI3K], GTPase activating protein of
ras, SHP-2, phospholipase C 1 [PLC]) were individually mutated. Based on in vitro results, the importance of
PDGF-initiated signals for neointima formation was investigated in genetically modified mice.
Results Our results indicate that the chemotactic response to PDGF requires the activation of Src, PI3K, and PLC,
whereas PDGF-dependent cell cycle progression is exclusively mediated by PI3K and PLC. These 2 signaling
molecules contribute to signal relay of the PDGFR by differentially regulating cyclin D1 and p27kip1. Blunting of
PDGFR-induced PI3K and PLC signaling by a combination mutant (F3) completely abolished the mitogenic
and chemotactic response to PDGF. Disruption of PDGF-dependent PI3K and PLC signaling in mice expressing
the F3 receptor led to a profound reduction of neointima formation after balloon injury.
Conclusions Signaling by the activated PDGFR, particularly through PI3K and PLC, is crucial for neointima formation after
vascular injury. Disruption of these specific signaling pathways is sufficient to attenuate pathogenic processes
such as vascular remodeling in vivo. (J Am Coll Cardiol 2011;57:2527–38) © 2011 by the American College of
Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2011.02.037Despite novel treatment options to achieve vessel patency
after percutaneous coronary interventions, vascular resteno-
sis remains a significant clinical problem (1). Critical events
for neointima formation at sites of vascular injury are the
attraction of vascular smooth muscle cells (VSMCs) from
the media, their neointimal proliferation, and extracellular
From the *Klinik III für Innere Medizin, Universität zu Köln, Köln, Germany;
†Center for Molecular Medicine Cologne, Universität zu Köln, Köln, Germany;
‡Centre for R&D, Uppsala University/County Council of Gävleborg, Gävle, Sweden;
§Institut für Pharmakologie, Charité-Universitätsmedizin Berlin, Berlin, Germany;
Institut für Pathologie, Universität zu Köln, Köln, Germany; ¶Abteilung für
Pharmakologie, Georg-August-Universität Göttingen, Göttingen, Germany; and the
#Department of Molecular Biology, University of Texas Southwestern Medicalmatrix deposition (1–3). The inhibition of central cell
cycle–regulating proteins such as mammalian target of
rapamycin is efficient in reducing neointima formation after
coronary stenting (4,5). However, this approach is ham-
pered by the burden of in-stent thrombosis, because mam-
malian target of rapamycin inhibition also restrains the
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PDGF Signaling in Neointima Formation June 21, 2011:2527–38proliferation of endothelial cells and
thus attenuates re-endothelialization
(6,7). Sophisticated novel therapeu-
tic approaches should selectively
target VSMC proliferation and
migration without affecting endo-
thelial cell function.
Platelet-derived growth factor
(PDGF) represents the most po-
tent mitogen and chemoattrac-
tant for VSMCs (8,9), whereas it
does not elicit significant effects
on endothelial cells. Further-
more, PDGF and its beta recep-
tor subtype (PDGFR), which is
abundantly expressed in VSMC
(10,11), are significantly up-
regulated and activated at sites of
vascular injury (12,13), making
the PDGFR a promising target
for therapeutic interventions.
However, recent studies on the
role of the PDGFR for neoin-
tima formation yielded conflict-
ing results (14,15). Although in-
ibition of PDGFR signaling was effective in reducing
estenosis formation in animal models, systemic administra-
ion of a PDGFR inhibitor failed to prevent the recurrence
f in-stent restenosis in humans. Therefore, it appears
rucial to more precisely define the role of PDGF for
eointima formation and to identify the signaling pathways
y which the PDGFR mediates cellular responses that
ontribute to vascular disease. We used a genetic approach
o address 3 important questions: 1) what are the signaling
athways that mediate PDGF-dependent migration and
roliferation in VSMCs; 2) is PDGFR signaling really
critical for neointima formation in vivo; and 3) can the
disruption of specific signaling pathways prevent neointima
formation? Upon ligand binding, the PDGFR recruits and
activates several SH2 domain-containing signaling mole-
cules that each stably associate with the receptor at phos-
phorylated tyrosine residues that serve as specific docking
sites (16). These include Src family kinases (Src), phospha-
tidylinositol 3-kinase (PI3K), the GTPase-activating pro-
tein of Ras (RasGAP), SHP-2, and phospholipase C1
PLC). To systematically investigate the role of each
individual signaling pathway, we used a series of chimeric
colony-stimulating factor-1 receptor (CSF1R)/PDGFR
utants in which the tyrosine residues required for binding
f each signaling molecule were individually replaced with
henylalanine (17). Using this system, we were able to
recisely characterize the signal relay mechanisms that
overn PDGF-dependent chemotaxis and cell cycle pro-
ression in VSMCs. These studies particularly identified
I3K and PLC as critical signaling enzymes in vitro.
Abbreviations
and Acronyms
BrdU 
5-bromodeoxyuridine
cdk  cyclin-dependent
kinase
ChiR  chimeric receptor
CSF1R  colony-
stimulating factor-1
receptor
ECM  extracellular matrix
M-CSF  macrophage
colony-stimulating factor
PDGF  platelet-derived
growth factor
PI3K  phosphatidylinositol
3-kinase
PLC  phospholipase C 1
RasGAP  GTPase
activating protein of ras
VSMC  vascular smooth
muscle cell
WT  wild typeonsequently, blunting of PDGF-dependent PI3K and nLC signaling in F3 mice, which lack the respective
binding sites in the PDGFR (18), dramatically reduced
eointima formation after vascular injury in vivo.
ethods
eneration of chimeric CSF1R/PDGFR mutants.
he chimeric receptor (ChiR) cDNA was constructed from
NA encoding amino acids 1 to 513 of the human CSF1R
nd amino acids 528 to 1,106 of the human PDGFR
joined at an EcoRI site (19). Mutations in the PDGFR
equence are as described (17).
nimals and diets. PDGFR-F3 mice were generated by
introducing point mutations into the PDGFR locus by
gene targeting as described (18). Male PDGFRF3/F3 mice
nd littermate wild-type (WT) controls (C57BL/6J) were
ept on a regular diet until experimentation. Mice were fed
chow diet (D12108 containing 1.25% cholesterol; Re-
earch Diets, New Brunswick, New Jersey) that was started
days before intervention and continued until harvesting.
ll animal experiments were performed in accordance with
nstitutional guidelines and approved by the local animal
ommittee.
ouse carotid balloon injury. Balloon injury of the left
roximal common carotid artery was performed in WT and
PDGFRF3/F3 mice (10 to 14 weeks of age) as described
(20). Briefly, the mid-common carotid artery was dilated to
approximately 1.3 times the unmanipulated diameter for
60 s, using a miniature angioplasty catheter (Schwager
Medica, Winterthur, Switzerland). Mice were euthanized
21 days after balloon injury. Vessels were perfusion fixed
with 4% paraformaldehyde. The injured left and the unin-
jured right common carotid artery were excised. After
post-fixation with 4% paraformaldehyde overnight, the
vessels were embedded in paraffin blocks and processed
further.
Morphometric analysis. Three serial cross-sections (5-m
thickness, 1,000 m apart) were taken from the mid-
portion of the dilated segment for histomorphological
analysis. Corresponding sections were obtained from the
uninjured right common carotid artery. Morphometric
analyses were performed using Image J analysis software
(National Institutes of Health, Bethesda, Maryland).
Immunoblotting. Quiescent VSMCs were left resting or
stimulated with 50 ng/ml of PDGF-BB or macrophage
colony-stimulating factor (M-CSF) for times indicated in
the presence or absence of inhibitors. Cells were washed and
lysed as described (21,22), and lysates were subjected to
immunoblot analysis.
Chemotaxis assay. PDGF-dependent chemotaxis was as-
sayed utilizing a 48-well modified Boyden chemotaxis
chamber (NeuroProbe Inc., Baltimore, Maryland) and
collagen-coated polyvinylpyrrolidone-free polycarbonate fil-
ters (8-m pore size) (Poretics Corp., Livermore, Califor-ia) as described (21,22).
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June 21, 2011:2527–38 PDGF Signaling in Neointima FormationDNA synthesis assay. DNA synthesis was measured by a
5-bromodeoxyuridine (BrdU)-incorporation assay, carried
out according to the manufacturer’s specifications (Roche,
Mannheim, Germany) with an incubation time of 5 h as
previously described (22).
Statistical analysis. All data are expressed as mean SEM.
Statistical significance of differences was calculated using anal-
ysis of variance with post-hoc Tukey test or Student unpaired
t test. p  0.05 was considered statistically significant.
Results
The main goal of our study was to investigate whether
selective blunting of PDGF-dependent VSMC prolifera-
tion and migration is sufficient to prevent neointima forma-
tion after vascular injury in vivo. To identify the crucial
targets for neointima prevention, we performed in vitro
studies utilizing chimeric CSF1R/PDGFR mutants
(ChiR) which contain the ligand-binding domain of the
CSF1R (c-fms) and the cytoplasmic domain of the WT or
mutated PDGFR (17). The subtraction panel contains
mutants in which the binding site for either one of the
PDGFR -associated signaling enzymes is mutated (Fig. 1A).
The add-back panel is based on the F5 receptor and contains
mutants that have the binding sites for one of the associated
proteins restored (Fig. 1B). A kinase inactive mutant (R634)
served as a negative control. The chimeric approach enabled us
to selectively stimulate PDGF-dependent signaling cascades
via ChiR mutants by M-CSF and to bypass endogenous
PDGFR in VSMCs. The ChiR mutant-expressing cell lines
have been characterized previously (17).
Functionality of ChiR mutants in VSMCs. Because our
approach required that VSMCs do not express functional
CSF1R, we first compared their responsiveness to
PDGF-BB and M-CSF. As expected, stimulation of
non-transfected VSMCs with PDGF-BB led to tyrosine
phosphorylation of the PDGFR and to activation of
ownstream signaling molecules such as Erk1/2. In
ontrast, M-CSF did not mediate the tyrosine phosphor-
lation of the CSF1R and did not induce Erk phosphor-
lation in VSMCs (Fig. 2A), whereas it triggered these
esponses in human monocytes (not shown). M-CSF
riggered the phosphorylation of downstream signaling
olecules such as Akt, Erk, and p38, and VSMC
igration and proliferation in ChiR-WT– expressing
ells to a similar extent as PDGF-BB in non-transfected
ells (Figs. 2B, 2C, and 2D). These data demonstrate
hat the system of ChiR mutants allows the systematic
valuation of PDGFR signaling in VSMCs without the
eed for pharmacological inhibitors.
I3-kinase and phospholipase C mediate the PDGFR’s
itogenic signal. Stimulation of ChiR-WT expressing
ells resulted in a concentration-dependent increase in BrdU
ptake (Fig. 3A). Deletion of the binding sites for PI3K
F40/51) or PLC (F1021) almost completely suppressed
NA synthesis even at saturating ligand concentrations,hereas deletion of the Src binding site (F79/81) led to an
nhanced mitogenic response. The latter is consistent with
revious reports, identifying Src as a negative regulator of
DGFR signaling (21). ChiR mutants that only bind either
I3K (Y40/51) or PLC (Y1021) were able to partially
mediate the ChiR-WT response (Fig. 3B). A potential
caveat of utilizing receptor mutants is the possibility that in
addition to the known binding partners of phospho-
tyrosines, other unknown signaling molecules may also
interact with these sites. Therefore, all measurements were
repeated in a second approach in PDGF-stimulated
VSMCs in the presence of pharmacological inhibitors.
Figure 1 Schematic Diagram Illustrating the Cytoplasmic
PDGFR Domain of Chimeric Receptor Mutants
Tyrosine phosphorylation sites are represented as P, and Tyr-to-Phe substitu-
tions are indicated as black squares. The signaling enzymes that associate
with the receptor are shown at the top of the schemes. The nomenclature of
the substraction panel (A) and add-back panel (B) of chimeric receptor (ChiR)
mutants is indicated to the right of each receptor representation. In the sub-
traction panel, the names indicate which of the Tyr residues have been
replaced with Phe (“F-mutants”), and in the add-back panel, the name of each
mutant denotes which of the mutations in the F5 construct has been repaired
(“Y-mutants”). JM  juxtamembrane; KI  kinase insert; PI3K  phosphatidyl-
inositol 3-kinase; PLC  phospholipase C 1; RasGAP  GTPase activating
protein of ras.Consistent with the findings obtained by the ChiR system,
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PDGF Signaling in Neointima Formation June 21, 2011:2527–38pharmacological inhibition of PI3K or PLC suppressed
PDGF-BB mediated BrdU incorporation (Fig. 3C). Fur-
thermore, inhibition of MEK1/2 also led to a decrease of
VSMC proliferation, whereas suppression of p38 activity
had no effect.
Multiple signaling enzymes are required for PDGF-dependent
chemotaxis. Stimulation of ChiR-WT expressing VSMCs
led to an increase in cell migration to approximately 4-fold
Figure 2 The M-CSF–Stimulated ChiR-WT Mimics PDGF-Induced
(A) Responsiveness of naive vascular smooth muscle cells (VSMCs) to platelet-de
(M-CSF) (50 ng/ml). Shown are immunoblots probed with antibodies recognizing p
phospho-Erk. (B) Activation of downstream signaling molecules in PDGF-BB–stimu
(WT)–expressing cells. (C) Comparison of the chemotactic response of naive VSM
Comparison of growth factor–dependent cell cycle progression in PDGF-BB– or M-C
means  standard error of the mean from at least 3 independent experiments (*pthe basal level (Fig. 4A). Mutation of the Src binding site(F79/81) almost completely abolished M-CSF–induced
chemotaxis, and mutation of the binding sites for PI3K
(F40/51) or PLC (F1021) significantly reduced M-CSF–
dependent chemotaxis by 55% and 60%, respectively. Acti-
vation of either 1 signaling molecule alone (add-back panel)
was not sufficient to rescue the chemotactic response
(Fig. 4B). Consistent with the use of ChiR mutants,
pharmacological inhibition of Src abolished PDGF-
ponses in VSMCs
rowth factor (PDGF)-BB (50 ng/ml) and macrophage colony-stimulating factor
o-tyrosine (P-Y), GTPase activating protein of ras (RasGAP) (lysate control), and
aive VSMCs and M-CSF–stimulated chimeric receptor (ChiR) wild-type
PDGF-BB (10 ng/ml) and ChiR-WT–expressing cells to M-CSF (10 ng/ml). (D)
imulated naive or ChiR-WT–expressing VSMCs as indicated. Data represent
05 vs. buffer).Res
rived g
hosph
lated n
Cs to
SF–st
 0.dependent chemotaxis in naive VSMCs, whereas inhibition
a
V
P
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June 21, 2011:2527–38 PDGF Signaling in Neointima Formationof either PI3K or PLC led to a partial inhibition of this
response (Fig. 4C). These data indicate that PI3K, PLC,
nd Src are required for PDGF-dependent chemotaxis in
Figure 3 Role of Signal Relay Enzymes in PDGF
Beta Receptor–Mediated DNA Synthesis
Vascular smooth muscle cells (VSMCs) expressing either the chimeric receptor
(ChiR) wild-type (WT), the subtraction panel of ChiR mutants (A), or the add-back
panel of ChiR mutants (B) were arrested by serum deprivation and exposed to buf-
fer or various concentrations of macrophage colony-stimulating factor (M-CSF). DNA
synthesis was measured by 5-bromodeoxyuridine (BrdU) incorporation. Data are
expressed as fold increase over buffer. (C) Effect of pharmacological inhibitors
against phosphatidylinositol 3-kinase (LY294002), phospholipase C 1 (U73122),
MEK (U0126), and p38 (SB203580) on platelet-derived growth factor (PDGF)-BB–
dependent cell cycle progression in non-transfected VSMCs. Data are expressed
as the percentage of PDGF-BB–stimulated cells. All data represent mean  stan-
dard error of the mean from at least 3 independent experiments (*p  0.05 vs.
WT at 50 ng/ml M-CSF, #p  0.05 vs. PDGF alone).SMCs.I3K and PLC differentially regulate the expression of
cyclin D1 and p27kip1. Growth factors regulate the cell
cycle from the exit from G0 until late G1. Phosphorylation
of the retinoblastoma protein (Rb) depends on G1 cyclin-
dependent kinases (cdks), which are activated by G1 cyclins
and inhibited by cdk inhibitors. The main growth factor–
induced events in early G1 are the up-regulation of cyclin
D1 and the down-regulation of the cdk inhibitor p27Kip1
(23). Stimulation of the endogenous PDGFR with
Figure 4 Role of Signal Relay Enzymes in PDGF
Beta Receptor–Mediated Chemotaxis
(A) Subtraction panel of chimeric receptor (ChiR) mutants. (B) Add-back panel of
ChiR mutants. (C) Naive vascular smooth muscle cells that have been stimulated
with platelet-derived growth factor (PDGF)-BB in the presence of pharmacological
inhibitors against phosphatidylinositol 3-kinase (LY294002), phospholipase C 1
(U73122), Src (SU6656), and p38 (SB203580). All data represent mean  stan-
dard error of the mean from at least 3 independent experiments (*p  0.05 vs.
wild type; #p  0.05 vs. PDGF alone).
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PDGF Signaling in Neointima Formation June 21, 2011:2527–38PDGF-BB and ChiR-WT with M-CSF led to a time-
dependent increase of cyclin D1 expression and degradation
of p27kip1, resulting in efficient Rb phosphorylation at 24 h
(Figs. 5A and 5B). As expected, the F5 receptor did not
influence p27kip1 and cyclin D1 levels or mediate Rb
phosphorylation (not shown). When the various ChiR
mutants were compared for their ability to regulate cell cycle
controlling molecules, disruption of PI3K binding to the
ChiR (F40/51) abolished the induction of cyclin D1,
whereas binding of PI3K alone (Y40/51) was sufficient to
induce cyclin D1 expression (Figs. 5C and 5D). Conversely,
disruption of all other signaling pathways including PLC
(F1021) did not affect M-CSF–dependent cyclin D1 in-
duction (Fig. 5C, and not shown). Interestingly, the F40/51
mutation diminished the receptor’s capability to down-
regulate p27kip1 to a much lesser extent than the F1021
utation (Fig. 5C). Additionally, the Y1021 mutant but
ot the Y40/51 mutant was able to efficiently down-regulate
27kip1 (Fig. 5D). Pharmacological inhibition of PI3K in
aive VSMC completely suppressed PDGF-dependent cy-
lin D1 induction, whereas inhibition of PLC had no
influence (Fig. 5E). Conversely, inhibition of PLC abol-
ished the down-regulation of p27kip1, whereas inhibition of
PI3K had little effect. Hence induction of cyclin D1 is
primarily mediated by PI3K, whereas PLC primarily
promotes the degradation of p27kip1.
isruption of PDGF-dependent PI3K and PLC activ-
ity by a combination mutant. Based on the preceding
findings, we generated a combination mutant that lacks the
binding sites for PI3K and PLC (F3 receptor; Fig. 6A) in
an attempt to completely abolish PDGF-dependent prolif-
eration and migration. The chimeric F3 mutant was stably
expressed in VSMCs to a similar level than the ChiR-WT
and did not associate with either PI3K or PLC upon
stimulation with M-CSF (Figs. 6B and 6C). VSMCs
transfected with the F3 mutant were unable to mediate a
chemotactic or mitogenic signal upon M-CSF stimulation
(Figs. 6D and 6E) and failed to efficiently induce cyclin D1
or down-regulate p27kip1 in response to M-CSF (Fig. 6F).
Hence our in vitro studies identified PI3K and PLC as
main mediators of PDGF-dependent proliferation and
migration of VSMCs, and the F3 mutant appeared as the
ideal tool to verify their importance in vivo.
Disruption of PDGF-dependent PI3K and PLC sig-
naling abolishes neointima formation after balloon injury
in vivo. To evaluate the importance of PDGF-dependent
PI3K and PLC signaling for neointima formation in vivo,
e performed balloon injury in carotid arteries of mice that
re homozygous for the murine PDGFR F3 mutant.
SMCs derived from PDGFRF3/F3 mice neither elicited a
itogenic signal, nor were they able to migrate toward
DGF (Figs. 7A and 7B). Balloon injury was performed in
he common carotid arteries of male PDGFRF3/F3 mice
and littermate WT controls. Three weeks after balloon
injury, WT mice displayed a robust neointima formation at
the site of vascular injury, and this response was dramatically sreduced in mice harboring the F3 mutation (Fig. 7C).
Consequently, the intimal area and the intima-media ratio
were significantly decreased in PDGFRF3/F3 mice,
hereas the patent lumen area was increased (Table 1).
utward remodeling in the PDGFRF3/F3 mice was ex-
luded, and there were no detectable differences in SMC
ifferentiation markers and extracellular matrix (ECM)
omponents (Fig. 7C, Online Fig. 1A). Consistently, acti-
ation of PDGFR signaling in ChiR–expressing VSMCs
id not affect the expression of differentiation markers
smoothelin, smooth muscle myosin heavy chain, alpha
ctin) or induce ECM components such as collagens I and
a (Online Figs. 1B and 2). The decreased intimal area in
3/F3 mice was paralleled by a decreased number of
eointimal nuclei and proliferating VSMCs, whereas the
rea per nucleus (ECM index) was equal in WT and
PDGFRF3/F3 mice (Table 1), indicating that decreased
SMC accumulation rather than diminished matrix depo-
ition accounts for the reduced neointima formation.
iscussion
n this study, we systematically analyzed the contribution of
he activated PDGFR and its associated signaling mole-
ules to cellular responses of VSMCs in vitro and neointima
ormation in vivo. The data presented herein are consistent
ith the schematic diagram outlined in Figure 8 and allow
important conclusions: 1) signaling by the activated
PDGFR (particularly through PI3K and PLC) is crucial
for neointima formation after vascular injury; and 2) disrup-
tion of specific signaling pathways is sufficient to attenuate
pathogenic processes such as neointima formation and
constrictive vascular remodeling in vivo.
Although previous studies that applied pharmacological
approaches or neutralizing antibodies have indicated that
PDGF is an important contributor to neointima formation
(12,14), some studies argued against a significant role of
PDGF. For instance, the systemic administration of the
tyrosine kinase inhibitor imatinib failed to reduce the
recurrence of coronary in-stent restenosis after coronary
interventions in humans (15). To directly prove the impor-
tance of PDGFR-initiated signals for neointima forma-
tion and to identify the crucial signaling pathways, we took
advantage of a targeted genetic modification. In mice that
are homozygous for the F3 mutation, the PDGFR is
normally expressed but is unable to recruit and activate
PI3K and PLC upon ligand binding (18). Based on the
revious observations that deletion of either the PDGFR
or the PDGF-B gene resulted in embryonic lethality that
was in part due to vascular defects, the fact that F3/F3 mice
are viable and have no obvious phenotype appears rather
surprising (18). However, chimeric analysis revealed that
when F3-receptor– bearing cells competed with WT
PDGFR-bearing cells in the same animals, there was a
strong selection against PDGFRF3/F3 cells in the layer of
mooth muscle cells surrounding the vasculature. This
2533JACC Vol. 57, No. 25, 2011 Caglayan et al.
June 21, 2011:2527–38 PDGF Signaling in Neointima FormationFigure 5 Regulation of Cell Cycle–Controlling Proteins Through PI3K and PLC
(A) Platelet-derived growth factor (PDGF)-BB causes induction of cyclin D1 and down-regulation of p27 kip1 protein at 24 h, resulting in retinoblastoma protein phosphory-
lation (P-Rb). (B) The activated chimeric receptor wild type (ChiR-WT) mimics the PDGF-BB–induced response in naive vascular smooth muscle cells (VSMCs). (C) Regula-
tion of cyclin D1 and p27 kip1 by the ligand-induced F40/51 and F1021 mutants. (D) Regulation of cyclin D1 and p27 kip1 by the ligand-induced Y40/51 and Y1021
mutants. (E) Naive VSMCs were treated with 50 ng/ml of PDGF-BB for 24 h in the presence of pharmacological inhibitors of phosphatidylinositol 3-kinase (PI3K;
LY294002) or phospholipase C 1 (PLC; U73122). (B to D) Cyclin D1 and p27kip1 signals were scanned and quantified by densitometry, and the values were normal-
ized for GTPase activating protein of ras (RasGAP) levels (lysate control). Data represent mean  standard error of the mean from 3 independent experiments (*p 
0.05, #p  0.01 vs. buffer).
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PDGF Signaling in Neointima Formation June 21, 2011:2527–38finding, which indicates that the F3 mutant receptor does
not transmit signals as efficiently as the WT receptor in vivo,
prompted us to hypothesize that the F3 mutation may
become relevant under pathological conditions. Indeed,
when we performed balloon injury in the carotid arteries of
PDGFRF3/F3 mice, the remodeling process at the site of
vascular injury was profoundly reduced when compared with
that of WT mice.
Our results are in line with findings of other investigators
showing that inhibition of PDGFR signaling by the use of
Figure 6 Blunting of Mitogenic and Chemotactic Signaling by a
That Lacks the PI3K and PLC Binding Sites (F3 R
(A) Schematic diagram illustrating the cytoplasmic domain of the chimeric rece
740/51 and 1021. (B) Expression levels of ChiR-F3 in comparison with ChiR-w
growth factor beta receptor–associated signaling molecules in quiescent and m
expressing cells. (D, E) M-CSF–dependent chemotaxis and cell cycle progressi
of M-CSF on cyclin D1 and p27kip1 levels in ChiR-F3 expressing VSMCs. Data i
WT). BrdU  5-bromodeoxyuridine; CSF1R  colony-stimulating factor-1 receptoyrosine kinase inhibitors or neutralizing antibodies pre- hented restenosis formation (12,14), as well as other conse-
uences of vascular remodeling, such as atherogenesis and
ulmonary arterial hypertension (24,25). The failure of oral
matinib to prevent the recurrence of in-stent restenosis in
umans as shown by Zohlnhöfer et al. (15) does not discard
he role of PDGF in this context, but may be explained by
everal reasons, including insufficient dosage, nonspecific
nhibition of several tyrosine kinases instead of specific
DGF receptor inhibition, systemic instead of local appli-
ation, and subtherapeutic tissue concentrations. Indeed, it
bination Mutant
or)
ChiR)-F3 mutant harboring Tyr-to-Phe substitutions at tyrosine residues
e (WT)–expressing cells. (C) Binding characteristics of platelet-derived
hage colony-stimulating factor (M-CSF)–stimulated ChiR-WT and ChiR-F3
WT and ChiR-F3 expressing vascular smooth muscle cells (VSMCs). (F) Effect
d E represent mean  SEM from 3 independent experiments (*p  0.05 vs.
er abbreviations as in Figure 1.Com
ecept
ptor (
ild typ
acrop
on in
n D an
r; othas been suggested that imatinib administered orally may
2535JACC Vol. 57, No. 25, 2011 Caglayan et al.
June 21, 2011:2527–38 PDGF Signaling in Neointima Formationnot reach sufficient serum concentrations (10 mol/l) to
function as a potent inhibitor of PDGFR signaling in
tissues (26). Our genetic approach circumvents the problem
Figure 7 Disruption of PDGF-Dependent PI3K and PLC Signali
(A, B) Platelet-derived growth factor (PDGF)–dependent cell cycle progression and
receptor (PDGFR)-F3/F3 mice (*p  0.05 vs. WT-mouse aortic smooth muscle ce
ing; 100; inset: 400; alpha-smooth muscle actin and Sirius red staining) of un
mate WT controls 3 weeks after balloon injury.
Morphometric Analyses of Carotid Arteries From WGr wth Factor Beta Receptor F3/F3 Mice 21Table 1 Morphometric Analyses of Carotid AGrowth Factor Beta Receptor F3/
Intimal Area (m2) Medial A
WT (n  10) 19,276 5,409 30,071
F3/F3 (n  11) 6,309 978* 28,887
Intimal Nuclei
WT (n  8) 88.58 29.66
F3/F3 (n  7) 28.19 10.43Values are mean  SEM. *p  0.05 versus WT.
ECM  extracellular matrix; PCNA  proliferating cell nuclear antigen; WTthat a pharmacological agent may not reach sufficient tissue
concentrations or may inhibit other unknown kinases and
clearly showed that blunting of PDGF-dependent PI3K
tenuates Neointima Formation In Vivo
taxis in vascular smooth muscle cells isolated from wild type (WT) or PDGF beta
ASMC]). (C) Representative histological cross-sections (hematoxylin eosin stain-
and injured common carotid arteries from male PDGFRF3/F3 mice and litter-
Platelet-DerivedAf r Balloon Injurys From WT r Platelet-Derived
ice 21 Days After Balloon Injury
m2) Lumen Area (m2) Intima-Media Ratio
58 44,982 9,130 0.64 0.19
27 79,780 8,689* 0.23 0.03*
Index (m2/cell) PCNA Positive Cells (%)
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PDGF Signaling in Neointima Formation June 21, 2011:2527–38and PLC activity in vivo dramatically reduces neointima
formation and constrictive arterial narrowing after vascular
injury.
PDGF is known to exert mitogenic and migratory re-
sponses in VSMCs, both of which are thought to contribute
to neointima formation. Previous studies have shown that
neointimal VSMC accumulation in the first days after
balloon injury occurs as a result of PDGF-dependent
VSMC migration from the media to the intima (27).
Although we did not particularly determine VSMC migra-
tion in our in vivo model, we show that the PDGFR F3
mutation significantly reduced the number of proliferating
VSMCs in the intima at 21 days after injury and that
mutation of the PI3K and PLC binding sites abolished
both PDGF-dependent VSMC proliferation and che-
motaxis in vitro. Taken together, these data indicate that
PDGF-dependent migration and proliferation are both
important for neointima formation and that disruption of
PDGF mediated PI3K and PLC signaling attenuates this
Figure 8
Schematic Diagram Illustrating the Differential
Roles of PDGF-Dependent PI3K and PLC Activity for
Cellular Responses and Neointima Formation In Vivo
Upon ligand binding, the platelet-derived growth factor (PDGF) beta receptor
recruits multiple signaling molecules, including phosphatidylinositol 3-kinase
(PI3K) and phospholipase C 1 (PLC). Although PI3K is required for efficient
up-regulation of cyclin D1, PLC is mainly responsible for down-regulation of
p27kip1. Both events are required for retinoblastoma protein (Rb) phosphoryla-
tion, which is crucial for cellular events such as cell cycle progression and che-
motaxis. At least in mice, these events appear to be crucial for neointima
formation after balloon injury. CDK  cyclin-dependent kinase.process after balloon injury by affecting both responses.The approach to investigate vascular remodeling in
PDGFRF3/F3 mice was based on in vitro experiments
utilizing chimeric CSF1R/PDGFR mutants that allowed
he systematic characterization of PDGFR signaling in
SMCs. We found that multiple signaling enzymes includ-
ng PI3K, PLC, and Src contribute to PDGF-dependent
chemotaxis. Because the directed migration of cells requires
a number of cellular events, it is likely that each of the
signaling molecules contributes to PDGF-mediated che-
motaxis in a different way. Previous studies have indicated
that PI3K- and PLC-dependent pathways are involved in
actin rearrangement, cytoskeletal changes, and lamellipodia
formation (28–31), whereas Src activity may be crucial for
the direction of cellular movement by mediating receptor
tyrosine kinase internalization and cap formation in 1 region
of the cell (32). In contrast to chemotaxis, PDGFR-
ediated cell cycle progression depends on 2 of the
eceptor-associated signaling molecules, PI3K and PLC.
hese results are consistent with a previous study in HepG2
ells (33). Although deletion of the binding sites for PI3K
r PLC almost completely abrogated DNA synthesis, the
estoration of either binding site in the F5 receptor partially
escued PDGFR-mediated proliferation. This may be
xplained by the fact that in contrast to the add-back
utants, the subtraction mutants (F40/51 and F1021) both
ind and activate negative regulators of PDGFR signaling
uch as RasGAP and SHP-2 (16). Rat VSMCs expressing
he F3 mutant and murine VSMCs isolated from
PDGFRF3/F3 mice were not able to mediate a mitogenic
r chemotactic signal, indicating that the inability of the
PDGFR to associate with PI3K and PLC fully abrogated
these responses. Our genetic approach bears one potential
caveat: We cannot completely rule out that proteins other
than the known binding partners of the mutated tyrosine
residues also associate with these sites and thereby contrib-
ute to PDGFR-mediated proliferation or migration.
However, this seems very unlikely because pharmacological
inhibition of PI3K or PLC also abrogated these cellular
responses. In addition to mouse and rat VSMCs, we found
that pharmacological inhibition of PI3K and PLC also
ttenuated PDGF-induced chemotaxis and proliferation of
uman coronary VSMCs (not shown), suggesting species
ndependency.
Our further investigations focused on cyclin D1 and
27kip1, which are critical for both cell cycle progression and
hemotaxis (23,34,35). Although the role of PI3K for the
egulation of cell cycle–controlling proteins has been ad-
ressed in multiple studies, the importance of PLC in this
ontext was less clear. Our data indicate that PI3K and
LC regulate cell cycle progression at least in part in a
on-redundant manner. PI3K was identified as the main
egulator of PDGFR-dependent cyclin D1 expression,
whereas PLC appeared to be of minor importance for this
event. This is consistent with other studies demonstrating
that cyclin D1 is mainly regulated by PI3K in numerous
systems (36–38). Surprisingly, our comparative analysis
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regulation. A recent report demonstrated that PDGF-BB–
dependent degradation of p27Kip1 in VSMC is mediated by
shortening the half-life of p27Kip1 mRNA via an Erk1/2-
ependent pathway (39). Conventional protein kinase C
soforms that act downstream of PLC and contribute to
p27Kip1 degradation are known to activate Erk1/2. Consis-
ently, we found that inhibition of either Erk1/2 or protein
inase C almost completely abrogated PDGF-dependent
own-regulation of p27Kip1 (not shown), suggesting a
rominent role for these PLC effectors for the regulation
of p27Kip1. Nevertheless, p27kip1 seems to be differentially
egulated in different cell types and through different growth
actors, as PDGF-dependent degradation of p27kip1 in
broblasts occurs independently from PI3K and is con-
rolled by c-myc, whereas interleukin-2–induced repression
f p27kip1 requires PI3K and Akt (40). Hence, growth
factor–dependent degradation of p27kip1 may be targeted in
a cell-type–specific manner. Although both pathways were
found to be redundant to some extent, our comparative
approach identified PI3K as the main regulator of PDGF-
dependent induction of cyclin D1 in VSMCs, whereas
PLC mainly controls the expression of p27kip1.
onclusions
n summary, our data indicate that PI3K and PLC
mediate PDGFR-dependent proliferation and migration
of VSMCs and provide direct proof that these signaling
pathways are essential for neointima formation after vascular
injury in vivo. The identification of these signal relay
mechanisms provides the basis for the development of novel
therapeutic and preventive strategies that selectively target
VSMCs without affecting endothelial cell function.
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